>>**Entry Name: Omapatrilat,** USAN

Synonym(s): Octahydro-4-[(2-mercapto-1-oxo-3-phenylpropyl)amino]-5-oxo-7*H*-pyrido[2,1-*b*][1,3]thiazepine-7-carboxylic acid, 9CI. BMS 186716



(3'*S*,4*S*,7*S*,10*aR*)-*form*

CAS Registry Number: 167305-00-2

Molecular Formula: $C_{19}H_{24}N_2O_4S_2$
Molecular Weight: 408.542
Accurate Mass: 408.117748
Percentage Composition: C 55.86%; H 5.92%; N 6.86%; O 15.66%; S 15.70%
Biological Use/Importance: Potent angiotensin-converting enzyme (ACE) and neutral endopeptidase (NEP) inhibitor. May be useful for the treatment of hypertension and congestive heart failure
Development Status: Phase II clinical trials (1997)

>>**Variant:** (3'*S*,4*S*,7*S*,10*aR*)-form

Molecular Formula: $C_{19}H_{24}N_2O_4S_2$
Molecular Weight: 408.542
Accurate Mass: 408.117748
Percentage Composition: C 55.86%; H 5.92%; N 6.86%; O 15.66%; S 15.70%
Physical Description: Solid
Melting Point: Mp 218-220 dec.°
Optical Rotation: $[\alpha]_D$ –78.9 (c, 0.46 in DMF)

References:

Eur. Pat., 1994, *Bristol-Myers Squibb*, 629 627; *CA*, **123**, 198836b, *(synth, pharmacol)*
Jemal, M. *et al.*, *J. Chromatogr., B: Biomed. Appl.*, 1997, **693**, 109-116; **698**, 123-132, *(hplc-ms)*
Robl, J.A. *et al.*, *J. Med. Chem.*, 1997, **40**, 1570-1577, *(synth, pharmacol, pmr, cmr, ir)*
Trippodo, N.C. *et al.*, *Am. J. Hypertens.*, 1998, **11**, 363-372, *(pharmacol)*
Graul, A. *et al.*, *Drugs of the Future*, 1999, **24**, 269-277